Effect of LY293111 in combination with gemcitabine in colonic cancer

Rene Hennig; Xian Zhong Ding; Wei Gang Tong; Richard C. Witt; Borko D. Jovanovic; Thomas E. Adrian

doi:10.1016/j.canlet.2004.02.023

Effect of LY293111 in combination with gemcitabine in colonic cancer

Rene Hennig, Xian Zhong Ding, Wei Gang Tong, Richard C. Witt, Borko D. Jovanovic, Thomas E. Adrian^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B₄ (LTB₄) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB₄ receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option.

Original language	English (US)
Pages (from-to)	41-46
Number of pages	6
Journal	Cancer Letters
Volume	210
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2004.02.023
State	Published - Jul 8 2004
Externally published	Yes

Keywords

Colon cancer
Gemcitabine
Heterotopic xenografts
LY293111

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2004.02.023

Cite this

@article{3b68b43fe285443eaed6e45830099e8e,

title = "Effect of LY293111 in combination with gemcitabine in colonic cancer",

abstract = "New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option.",

keywords = "Colon cancer, Gemcitabine, Heterotopic xenografts, LY293111",

author = "Rene Hennig and Ding, {Xian Zhong} and Tong, {Wei Gang} and Witt, {Richard C.} and Jovanovic, {Borko D.} and Adrian, {Thomas E.}",

note = "Funding Information: Supported by grants from the National Cancer Institute SPORE program (CA72712), The American Institute for Cancer Research (00B065) and the Lilly Research Laboratories. RH received a fellowship award from the Deutsche Forschungsgemeinschaft (RH).",

year = "2004",

month = jul,

day = "8",

doi = "10.1016/j.canlet.2004.02.023",

language = "English (US)",

volume = "210",

pages = "41--46",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Effect of LY293111 in combination with gemcitabine in colonic cancer

AU - Hennig, Rene

AU - Ding, Xian Zhong

AU - Tong, Wei Gang

AU - Witt, Richard C.

AU - Jovanovic, Borko D.

AU - Adrian, Thomas E.

N1 - Funding Information: Supported by grants from the National Cancer Institute SPORE program (CA72712), The American Institute for Cancer Research (00B065) and the Lilly Research Laboratories. RH received a fellowship award from the Deutsche Forschungsgemeinschaft (RH).

PY - 2004/7/8

Y1 - 2004/7/8

N2 - New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option.

AB - New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option.

KW - Colon cancer

KW - Gemcitabine

KW - Heterotopic xenografts

KW - LY293111

UR - http://www.scopus.com/inward/record.url?scp=2542469678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542469678&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2004.02.023

DO - 10.1016/j.canlet.2004.02.023

M3 - Article

C2 - 15172119

AN - SCOPUS:2542469678

SN - 0304-3835

VL - 210

SP - 41

EP - 46

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Effect of LY293111 in combination with gemcitabine in colonic cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this